

## **A. LABELLING - OUTER PACKAGE**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Kesium 200 mg / 50 mg Chewable tablets for dogs

Amoxicillin (as amoxicillin trihydrate)  
Clavulanic acid (as potassium clavulanate)

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Each tablet contains:

**Active substance:**

Amoxicillin (as amoxicillin trihydrate)	200.00 mg
Clavulanic acid (as potassium clavulanate)	50.00 mg

**3. PHARMACEUTICAL FORM**

Chewable tablet

**4. PACKAGE SIZE**

1 x 8 tablets  
2 x 8 tablets  
4 x 8 tablets  
6 x 8 tablets  
8 x 8 tablets  
10 x 8 tablets  
12 x 8 tablets  
30 x 8 tablets  
60 x 8 tablets

**5. TARGET SPECIES**

Dogs

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD**

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Any divided tablet portions remaining after 36 hours should be discarded

**11. SPECIAL STORAGE CONDITIONS**

Do not store above 25°C.

Divided tablets should be stored in the blister pack

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only - to be supplied only on veterinary prescription

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Ceva Animal Health Ltd  
Explorer House  
Mercury Park  
Wycombe Lane  
Wooburn Green  
High Wycombe  
Buckinghamshire  
HP10 0HH  
United Kingdom

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 15052/4131

**17. MANUFACTURER'S BATCH NUMBER**

Batch:

## **A. LABELLING - BLISTER**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Kesium 200 mg / 50 mg Chewable tablets for dogs

Amoxicillin (as amoxicillin trihydrate)  
Clavulanic acid (as potassium clavulanate)

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

Ceva logo

**3. EXPIRY DATE**

EXP {month/year}

**4. BATCH NUMBER**

Batch:

**5. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only

## **B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

Kesium 200 mg / 50 mg Chewable tablets for dogs

### 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

Ceva Animal Health Ltd  
Explorer House  
Mercury Park  
Wycombe Lane  
Wooburn Green  
High Wycombe  
Buckinghamshire  
HP10 0HH  
United Kingdom

Manufacturer responsible for batch release:

Ceva Santé Animale  
Boulevard de la Communication  
Zone Autoroutière  
53950 LOUVERNE  
FRANCE

### 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Kesium 200 mg / 50 mg Chewable tablets for dogs

Amoxicillin (as amoxicillin trihydrate)  
Clavulanic acid (as potassium clavulanate)

### 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each tablet contains:

**Active substance:**

Amoxicillin (as amoxicillin trihydrate)	200.00 mg
Clavulanic acid (as potassium clavulanate)	50.00 mg

Chewable tablet

Clover-shaped scored beige tablet. The tablet can be divided into four equal parts

### 4. INDICATION(S)

For the treatment of the following infections caused by  $\beta$  lactamase producing strains of bacteria sensitive to amoxicillin in combination with clavulanic acid and where clinical experience and/or sensitivity testing indicates the product as the drug of choice:

- Skin infections (including superficial and deep pyodermas) associated with *Staphylococcus* spp.
- Urinary tract infections associated with *Staphylococcus* spp, *Streptococcus* spp, *Escherichia coli* and *Proteus mirabilis*.
- Respiratory tract infections associated with *Staphylococcus* spp, *Streptococcus* spp and *Pasteurella* spp.
- Digestive tract infections associated with *Escherichia coli*.
- Infections of the oral cavity (mucous membrane) associated with *Pasteurella* spp, *Streptococcus* spp, *Escherichia coli*.

## 5. CONTRAINDICATIONS

Do not use in animals with known hypersensitivity to penicillins or other substances of the  $\beta$ -lactam group or to any excipients.

Do not use in animals with serious dysfunction of the kidneys accompanied by anuria and oliguria.

Do not administer to gerbils, guinea pigs, hamsters, rabbits and chinchillas. Do not use in horses and ruminating animals.

Do not use where resistance to this combination is known to occur.

## 6. ADVERSE REACTIONS

Mild gastrointestinal signs (diarrhoea, and vomiting) have been reported in very rare cases (less than 1 animal in 10,000 animals, including isolated reports) after administration of the product. Treatment may be discontinued depending on the severity of the undesirable effects and a benefit/risk evaluation by the veterinary surgeon.

Allergic reactions (skin reactions, anaphylaxis) have been reported in very rare cases (less than 1 animal in 10,000 animals, including isolated reports). In these cases, administration should be discontinued and a symptomatic treatment given.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

## 7. TARGET SPECIES

Dogs



## 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

The recommended dose of the product is 10 mg amoxicillin /2.5 mg clavulanic acid per kg body weight twice a day by the oral route in dogs, i.e. 1 tablet per 20 kg body weight every 12 h, according to the following table:

Body weight (kg)	Number of tablets twice daily
> 2.6 to 5.0	$\frac{1}{4}$
> 5.1 to 10.0	$\frac{1}{2}$
> 10.1 to 15.0	$\frac{3}{4}$
> 15.1 to 20.0	1
> 20.1 to 25.0	1 $\frac{1}{4}$
> 25.1 to 30.0	1 $\frac{1}{2}$
> 30.1 to 35.0	1 $\frac{3}{4}$
> 35.1 to 40.0	2

In refractory cases the dose may be doubled to 20 mg of amoxicillin / 5 mg clavulanic acid/kg bodyweight twice daily, at the clinician's discretion.

### Duration of therapy

The majority of routine cases respond to 5 – 7 days of therapy.

In chronic cases, a longer case of therapy is recommended. In such circumstances overall treatment length must be at the clinician's discretion, but should be long enough to ensure complete resolution of the bacterial disease.

To ensure the correct dosage, body weight should be determined as accurately as possible to avoid under-dosing.

## 9. ADVICE ON CORRECT ADMINISTRATION

The chewable tablets are flavoured and are accepted by a majority of dogs. The chewable tablets can be administered directly into the mouth of the animals or added to a small quantity of food.

Instruction on how to divide the tablet: Put the tablet on an even surface, with its scored side facing down (convex face up). With the tip of the forefinger, exert slight vertical pressure on the middle of the tablet to break it along its width into halves. Then, in order to obtain quarters, exert slight pressure on the middle of one half with the forefinger to break it into two parts.

## 10. WITHDRAWAL PERIOD

Not applicable.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

Do not store above 25°C.

Divided tablets should be stored in the blister pack

Any divided tablet portions remaining after 36 hours should be discarded

Do not use this veterinary medicinal product after the expiry date which is stated on the blister and the carton. The expiry date refers to the last day of that month.

## **12. SPECIAL WARNING(S)**

### **i) Special precautions for use in animals**

Official, national and regional antimicrobial policies with respect to the use of broad-spectrum antibiotics should be taken into account.

Do not use in case of bacteria sensitive to narrow spectrum penicillins or to amoxicillin as single substance.

It is advised that upon initiating therapy appropriate sensitivity testing is performed and that therapy is continued only after susceptibility to the combination has been established.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the amoxicillin/clavulanate, and may decrease the effectiveness of treatment with beta-lactam antibiotics

In animals with hepatic and renal dysfunction, the dosing regimen should be carefully evaluated and the use of the product based on a risk/benefit evaluation by the veterinary surgeon.

Caution is advised in the use in small herbivores other than those in the section "Contraindications".

The potential for allergic cross-reactions with other penicillin derivatives and cephalosporins should be considered

The chewable tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals

### **ii) Special precautions to be taken by the person administering the veterinary medicinal product to animals**

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.

Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.

Handle this product with great care to avoid exposure, taking all recommended precautions.

If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and require urgent medical attention.

Wash hands after use.

**Use during pregnancy, lactation or lay**

Laboratory studies in rats and mice have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects.

In pregnant and lactating animals, use only according to the benefit/risk assessment by the responsible veterinarian.

**Interaction with other medicinal products and other forms of interaction**

Chloramphenicol, macrolides, sulfonamides and tetracyclines may inhibit the antibacterial effect of penicillins because of the rapid onset of bacteriostatic action.

Penicillins may increase the effect of aminoglycosides.

**Overdose (symptoms, emergency procedures, antidotes), if necessary**

In case of overdose diarrhoea, allergic reactions or further symptoms like central nervous excitation manifestations or cramps could appear. Symptomatic treatment should be initiated when necessary.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

**15. OTHER INFORMATION**

Pack sizes:

Cardboard box with 1 blister of 8 tablets

Cardboard box with 2 blisters of 8 tablets

Cardboard box with 4 blisters of 8 tablets

Cardboard box with 6 blisters of 8 tablets

Cardboard box with 8 blisters of 8 tablets

Cardboard box with 10 blisters of 8 tablets

Cardboard box with 12 blisters of 8 tablets

Cardboard box with 30 blisters of 8 tablets

Cardboard box with 60 blisters of 8 tablets

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

Local representative:

Revised: June 2023  
AN: 03887/2022 & 03891/2022

Approved 12 June 2023

A handwritten signature in black ink, appearing to read "J. Hunter.", is positioned below the approval date. The signature is stylized and includes a period at the end.